Participated · Series A · Jul 2026

OXMIQ develops a licensable GPU core, OxCore™, that integrates a CUDA-compatible GPU engine, a tensor processing engine, and an orchestration engine to enable configurable AI silicon. Its OxQuilt™ chiplet integration architecture supports heterogeneous compute and memory configurations across foundries and packaging options, and OxPython™ and OxCapsule™ provide software portability and orchestration for running existing CUDA and PyTorch code. OxCore is running on FPGA today with live demonstrations available, and the company positions an IP-first model to generate revenue from customer engagements while conserving capital. OXMIQ is working with semiconductor companies, neoclouds, AI system builders, and partners such as MediaTek and AM Intelligence Labs on initiatives including a renewable-powered AI factory collaboration. The company has strengthened its governance with additions to its board and advisory ranks to support customer integration and scaling. Financially, OXMIQ has raised $60 million in total capital following the $35 million Series A.

Participated · Series A · Jun 2025

Tacta Systems is a Palo Alto-based robotics company developing Dextrous Intelligence, a smart nervous system that gives robots human-level tactile skills and spatial awareness. Its proprietary combination of software, hardware and AI enables robots to sense, adapt, and manipulate the physical world with human-like precision and speed. The company targets industrial and consumer applications, aiming to perform delicate, variable, human-like tasks with flexibility, efficiency and autonomy. Tacta says its technology will help automate factory work and physically grueling labor. Founded by serial entrepreneurs and led by co-founder and CEO Andreas Bibl, the company announced new funding to accelerate development of its robotic solutions.

Participated · Series B · May 2024

TXOne Networks develops cybersecurity solutions to ensure the reliability and safety of industrial control systems and operational technology environments. The company offers both network-based and endpoint-based products to secure OT networks and mission-critical devices using a real-time, defense-in-depth approach. TXOne works with leading manufacturers and critical infrastructure operators to deliver operations-friendly cyber defense, including advanced threat detection and response to counter ransomware and other emergent strategic threats. TXOne secures the operations of more than 3,600 organizations globally across industries including semiconductors, automotive, pharmaceutical, food and beverage, public transportation, utilities, electronics, healthcare, mining and metals, oil and gas, and aerospace. In April 2024 TXOne announced the SageOne central management console to manage the CPS attack surface across OT, combining advanced technologies with a user-friendly interface and enabling integrated lifecycle protection. The company recently raised $51 million in a Series B extension, reflecting investor confidence in continued product and platform development. TXOne Networks, headquartered in Irving, Texas and Taipei, Taiwan, is a global leader in IIoT and OT cybersecurity. The company positions itself as a pioneer of an "OT zero trust" approach and offers both network-based and endpoint-based products to secure industrial control systems in real time. TXOne serves large enterprises, international conglomerates and upstream‑to‑downstream supply chains across sectors including semiconductor, medical and pharmaceutical, automobile, aerospace, smart manufacturing, food processing, public transportation and critical electric infrastructure. The firm was recognized by CRN as a 2022 Emerging Vendor in Security. Strong market demand contributed to a 107% year‑over‑year revenue increase in the first half of 2022; employment in Europe and the U.S. rose 67%, and total staff in Asia, Europe and the U.S. is expected to double by year‑end. TXOne plans to expand its global market presence and recruit talent to grow its OT zero‑trust cybersecurity platform. TXOne Networks develops cybersecurity solutions specifically for industrial control systems and the Industrial IoT. The company is a joint venture of Trend Micro and Moxa and is led by CEO Dr. Terence Liu. TXOne focuses on simplifying complex, fast-changing cybersecurity challenges encountered during digital transformation and on perfecting defense solutions for the ICS industry. The firm plans to use new funding to refine its ICS security products, expand business in certain regions, and strengthen marketing and after-sales service teams. Financially, TXOne has raised $23.7m since its founding and recently completed a Series A financing. It operates from Taipei and targets organizations undergoing industrial digital transformation.

Led · Series A · Feb 2024

Anbogen Therapeutics is a clinical-stage biotechnology company based in Taipei, Taiwan, focused on developing precision anti-cancer therapies. The company was founded by Dr. Joe Shih and is committed to R&D innovations to improve cancer patient outcomes. Two of its investigational drugs, ABT-101 for NSCLC with HER2 exon20 insertion mutations and ABT-301 (to be combined with immune checkpoint inhibitors) are currently in human clinical trials. Anbogen raised funding in a Series A+ to advance its pipeline. The company intends to use the proceeds to support a Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for microsatellite stable (MSS) metastatic colorectal cancer. The company highlights MSS metastatic colorectal cancer as comprising about 95% of the metastatic colorectal cancer population that does not benefit from immune checkpoint inhibitors. Anbogen Therapeutics is a clinical-stage biotech headquartered in Taipei, Taiwan, focused on developing precision anti-cancer small molecules. The company’s two lead candidates are ABT-101, a HER2-targeting tyrosine kinase inhibitor, and ABT-301, a small molecule that potentiates immune checkpoint inhibitors. ABT-101 has shown substantial potency and safety in preclinical studies and a phase 1b trial, with superior selectivity against HER2 exon 20 insertion mutations. ABT-301 completed a phase 1 trial and demonstrated superior safety and pharmacokinetic profiles versus similar marketed drugs; repeated animal studies show strong synergy with anti-PD‑1/PD‑L1 therapies, including activity in MSS colorectal cancer models and modulation of the tumor microenvironment to increase killer T cell infiltration. The company says clinical signs of safety and benefit have been observed in non-small cell lung cancer patients, including sustained tumor suppression in patients previously resistant to Enhertu. Led by CEO Dr. Tsu-An Hsu and General Manager Joe Hsueh, Anbogen positions its programs to address national medical needs and accelerate development toward improved cancer treatments.

Participated · Series A · Aug 2021

安立玺荣 is an innovative immunotherapy new‑drug developer committed to R&D for cancer, immune and neurological disease treatments. The company provides products including Alzheimer’s drugs and antibody biologics. It recently announced completion of a financing round totaling nearly RMB 100 million equivalent in USD‑denominated funds. The financing was supported by three dollar funds. The company said the round reflects international and domestic investors' recognition of its scientific innovation and execution capabilities. The report was published by DoNews citing IT桔子. Elixiron is developing therapeutics across cancer, neurological diseases and inflammatory disorders with a focus on reverse-translational immunotherapy approaches. The company operates in San Francisco, Taipei and Shanghai and was founded in 2017 under CEO and Chairman Hung-Kai Chen. It intends to use the Series A-1 funds to advance phase 1 trials of two pipeline candidates and to take three immuno-oncology assets toward IND applications. Pipeline highlights include EI-1071, an orally available, potent CSF1R inhibitor currently in a phase 1 trial and supported by an Alzheimer’s Association Part the Cloud‑Gates Partnership Grant, and EI-001, a fully human antibody targeting immuno-modulatory pathways in vitiligo and chronic hepatitis B. The executive team includes Pandelakis Koni (Executive VP of R&D) and Carrie Duan (Executive VP of Clinical Development).